Skip to main content
. 2022 May 30;7(3):100477. doi: 10.1016/j.esmoop.2022.100477

Figure 1.

Figure 1

Scores over time for (A) EORTC global health status and (B) FACT-C colorectal cancer. Mean change of baseline (±SE) over time for (A) EORTC global health status and (B) FACT-C colorectal cancer by visit for patients treated with encorafenib plus cetuximab with or without binimetinib, or control. Baseline was defined as the last assessment carried out on or before the date of the first dose of study treatment.BINI, binimetinib; BL, baseline; CETUX, cetuximab; FACT-C, Functional Assessment of Cancer Therapy—Colorectal; ENCO, encorafenib; EORTC, European Organization for Research and Treatment of Cancer Quality of Life of Questionnaire Core 30; EOT, end of treatment; F/UP, follow-up; SE, standard error.